Safety and efficacy of vaccination against streptococcus pneumonia in patients with rheumatic diseases

Autoimmunity Reviews

Volumn 6, Issue 5, 2007, Pages 312-314

  Elkayam, Ori ^a   Ablin, Jacob ^a   Caspi, Dan ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Pneumovax; RA; SLE; Vaccination

Indexed keywords

AUTOANTIBODY; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHOTREXATE; PNEUMOCOCCUS VACCINE; SALAZOSULFAPYRIDINE;

ANTIBODY RESPONSE; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; CLINICAL ASSESSMENT; DISEASE ACTIVITY; DISEASE COURSE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; PAIN ASSESSMENT; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; STREPTOCOCCUS PNEUMONIA; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME; VACCINATION; VISUAL ANALOG SCALE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG TOXICITY; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; STREPTOCOCCAL VACCINES; STREPTOCOCCUS PNEUMONIAE; TUMOR NECROSIS FACTOR-ALPHA; VACCINATION;

EID: 33947717333     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2006.09.005     Document Type: Review

References (22)

1. Symmons D.P., Jones M.A., Scott D.L., and Prior P. Longterm mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well. J Rheumatol 25 (1998) 1072-1077
2. Dubois E.L., Wierzchowiecki M., Cox M.B., and Weiner J.M. Duration and death in systemic lupus erythematosus: an analysis of 249 cases. JAMA 227 (1974) 1399-1402
3. Gabriel S.E., Crowson C.S., and O'Fallon W.M. Mortality in rheumatoid arthritis: have we made an impact in 4 decades?. J Rheumatol 26 (1999) 2529-2533
4. Steinberg A.D. Management of systemic lupus erythematosus. In: Kelley W.N., Harris Jr. E.D., Ruddy S., and Sledge C.B. (Eds). Textbook of rheumatology. 2nd ed. (1989), W.B. Saunders, Philadelphia 1130
5. Millykangas-Luosujarvi R., Aho K., Kautiainen H., and Isomaki H. Shortening of life span and causes of excess mortality in a population-based series of subjects with rheumatoid arthritis. Clin Exp Rheumatol 13 (1995) 149-153
6. Guedes C., Dumont-Fischer D., Leichter-Nakache S., and Boissier M.C. Mortality in rheumatoid arthritis. Rev Rhum Engl Ed 66 (1999) 492-498
7. Iliopoulos A.G., and Tsokos G.C. Immunopathogenesis and spectrum of infections in systemic lupus erythematosus. Semin Arthritis Rheum 25 (1996) 318-336
8. Listing J., Strangfeld A., Kary S., Rau R., von Hinueber U., Stoyanova-Scholz M., et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 52 (2005) 3403-3412
9. Anonymous. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 46 RR-8 (1997) 1-24
10. Sims R.V., Steinmann W.C., McConville J.H., King L.R., Zwick W.C., and Schwartz J.S. The clinical effectiveness of pneumococcal vaccine in the elderly. Ann Intern Med 108 (1988) 653-657
11. Schwartz J.S. Pneumococcal vaccine: clinical efficacy and effectiveness. Ann Intern Med 96 (1982) 208-220
12. Older S.A., Battafarano D.F., Enzenauer R.J., and Krieg A.M. Can immunization precipitate connective tissue disease? Report of five cases and review of the literature. Semin Arthritis Rheum 29 (1999) 131-139
13. Maillefert J.F., Sibilia J., Toussirot E., Vignon E., Eschard J.P., Lorcerie B., et al. Rheumatic disorders developed after hepatitis B vaccination. Rheumatology 38 (1999) 978-983
14. Elkayam O., Paran D., Caspi D., Litinsky I., Yaron M., Charboneau D., et al. Immunogenicity and safety of pneumococcal vaccination in patients with rheumatoid arthritis or systemic lupus erythematosus. Clin Infect Dis 34 (2002) 147-153
15. Kapetanovic M.C., Saxne T., Sjoholm A., Truedsson L., Jonsson G., and Geborek P. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology (Oxford) 45 (2006) 9-10
16. Elkayam O., Caspi D., Reitblatt T., Charboneau D., and Rubins J.B. The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum 33 (2004) 283-288
17. Mease P.J., Ritchlin C.T., Martin R.W., Gottlieb A.B., Baumgartner S.W., Burge D.J., et al. Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept. J Rheumatol 31 (2004) 1238-1240
18. Battafarano D.F., Battafarano N.J., Larsen L., Dyer P.D., Older S.A., Muehlbauer S., et al. Antigen-specific antibody responses in lupus patients following immunization. Arthritis Rheum 41 (1998) 1828-1834
19. McDonald E., Jarrett M.P., Schiffman G., and Grayzel A.I. Persistence of pneumococcal antibodies after immunization in patients with systemic lupus erythematosus. J Rheumatol 11 (1984) 306-308
20. Pisoni C., Sarano J., Benchetrit G., Rodriguez D., Suarez L., Perrota C., et al. Antipneumococcal vaccination in patient with systemic lupus erythematosus. Medicina (B Aires) 63 (2003) 388-392
21. Tarjan P., Sipka S., Marodi L., Nemes E., Lakos G., Gyimesi E., et al. No short-term immunological effects of Pneumococcus vaccination in patients with systemic lupus erythematosus. Scand J Rheumatol 31 (2002) 211-215
22. Elkayam O., Paran D., Burke M., Zakut V., Ben-Yitshak R., Litinsky I., et al. Pneumococcal vaccination of patients with systemic lupus erythematosus: effects on generation of autoantibodies. Autoimmunity 38 (2005) 493-496